Domača stranMRCK34 • BVMF
add
Merck Sharp & Dohme
Prejšnji trg. dan.
76,14 R$
Dnevni razpon
74,15 R$ - 76,14 R$
Letni razpon
60,19 R$ - 94,00 R$
Tržna kapitalizacija
254,59 mrd. USD
Povprečni obseg
6,13 tis.
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 16,66 mrd. | 4,35 % |
Stroški poslovanja | 8,40 mrd. | 48,81 % |
Čisti dohodek | 3,16 mrd. | −33,47 % |
Čista dobičkovnost prihodkov | 18,95 | −36,26 % |
Earnings per share | 1,57 | −26,29 % |
EBITDA | 5,51 mrd. | −21,97 % |
Efektivna davčna stopnja | 22,71 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 14,59 mrd. | 66,34 % |
Skupna sredstva | 117,53 mrd. | 10,12 % |
Skupne obveznosti | 72,97 mrd. | 11,53 % |
Celoten lastniški kapital | 44,56 mrd. | — |
Shares outstanding | 2,53 mrd. | — |
Razmerje P/B | 4,33 | — |
Donosnost sredstev | 9,48 % | — |
Donosnost kapitala | 13,29 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 3,16 mrd. | −33,47 % |
Denar iz dejavnosti | 9,29 mrd. | 20,40 % |
Denar iz naložb | −3,84 mrd. | −1.051,20 % |
Denar iz financiranja | −2,42 mrd. | 43,20 % |
Neto sprememba denarnih sredstev | 3,32 mrd. | 12,11 % |
Prost denarni tok | 7,42 mrd. | 28,97 % |
Vizitka
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Merck & Co. was originally established as the American affiliate of Merck Group in 1891. Merck develops and produces medicines, vaccines, biologic therapies and animal health products. It has several blockbuster products, including cancer immunotherapy, anti-diabetic medications, and vaccines for HPV and chickenpox, each generating significant revenue as of 2020.
The company is ranked 71st on the 2022 Fortune 500 and 87th on the 2022 Forbes Global 2000, both based on 2021 revenues. In 2023, the company’s seat in Forbes Global 2000 was 73. Wikipedia
Generalni direktor
Datum ustanovitve
1. jan. 1891
Spletno mesto
Zaposleni
71.000
